Increased Autoreactivity of the Complement-Activating Molecule Mannan-Binding Lectin in a Type 1 Diabetes Model

Abstract EN

Background.

Diabetic kidney disease is the leading cause of end-stage renal failure despite intensive treatment of modifiable risk factors.

Identification of new drug targets is therefore of paramount importance.

The complement system is emerging as a potential new target.

The lectin pathway of the complement system, initiated by the carbohydrate-recognition molecule mannan-binding lectin (MBL), is linked to poor kidney prognosis in diabetes.

We hypothesized that MBL activates complement upon binding within the diabetic glomerulus.

Methods.

We investigated this by comparing complement deposition and activation in kidneys from streptozotocin-induced diabetic mice and healthy control mice.

Results.

After 20 weeks of diabetes, glomerular deposition of MBL was significantly increased.

Diabetic animals had 2.0-fold higher (95% CI 1.6–2.5) immunofluorescence intensity from anti-MBL antibodies compared with controls ( P < 0.001 ).

Diabetes and control groups did not differ in glomerular immunofluorescence intensity obtained by antibodies against complement factors C4, C3, and C9.

However, the circulating complement activation product C3a was increased in diabetes as compared to control mice ( P = 0.04 ).

Conclusion.

20 weeks of diabetes increased MBL autoreactivity in the kidney and circulating C3a concentration.

Together with previous findings, these results indicate direct effects of MBL within the kidney in diabetes.